The Nexera MP UHPLC for LC/MS analysis in drug detection processes - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Nexera MP UHPLC for LC/MS analysis in drug detection processes

Shimadzu has introduced the Nexera MP UHPLC as a Front End system for LC/MS. The Nexera MP is perfect for LC/MS analysis conducted in pharmacokinetics and synthesis stages in drug detection processes.

The new SIL-30ACMP Multiplate Autosampler used in the Nexera MP is best suited for LC/MS analysis and has the industry-best micro-volume injection repeatability, the world’s highest injection speed and the lowest carryover. Combining the Nexera MP with Shimadzu’s LCMS-8030 Triple Quadrupole Mass Spectrometer or the LCMS-2020 Single Quadrupole Mass Spectrometer creates a system for quick analysis of multiple samples with high accuracy.

Additional outstanding features

  • Efficient sample preparation
    through excellent injection repeatability with micro volume injections streamlining the preparation process.
  • Two or more analyzers share one system
    supporting the reduction of energy consumption and operation costs.
  • Column oven setting to the MS position
    enabling achievement of ultra-high-speed, high-separation LC/MS analysis while maximizing the system’s separation performance.

The Nexera MP is controlled by Shimadzu’s LabSolutions software and major LC/MS workstations available from other companies.

For more details please visit www.shimadzu.eu.

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
22%
To all process for new products only
12%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search

Click here